MedTrace Logo

Thalidomide in Mucosa Associated Lymphoid Tissue (MALT) Lymphoma Patients

NCT00373646 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 8

Last updated 2009-06-18

No results posted yet for this study

Summary

The purpose of this study is to evaluate Thalidomide for treatment of disseminated MALT Lymphoma or at relapse following helicobacter pylori (HP) - eradication or chemotherapy or radiation.

Conditions

  • MALT Lymphoma

Interventions

DRUG

Thalidomide, Pharmion

200 mg p.o. daily

Sponsors & Collaborators

  • Medical University of Vienna

    lead OTHER

Principal Investigators

  • Markus Raderer, Prof · Department of Internal Medicine I

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-06-30
Primary Completion
2009-01-31
Completion
2009-01-31

Countries

  • Austria

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00373646 on ClinicalTrials.gov